219.80MMarket Cap-3.97P/E (TTM)
0.8424High0.7417Low9.15MVolume0.8238Open0.8321Pre Close7.18MTurnover3.19%Turnover RatioLossP/E (Static)291.32MShares2.105052wk High5.43P/B216.79MFloat Cap0.457852wk Low--Dividend TTM287.33MShs Float778.1999Historical High--Div YieldTTM12.10%Amplitude0.1700Historical Low0.7840Avg Price1Lot Size
Ocugen Stock Forum
GlobeNewswire· 5 mins ago
OCU410 has a very favorable safety and tolerability profileNo serious adverse events related to the study drug have been reported, such as exudation, infectious endophthalmitis, intraocular Inflammation, anterior ischemic optic neuropathy, or vasculitis
Grabbed a few at .88. It usually hovers around $1-2, a little upside
Ocugen Announces European Medicines Agency Grants Orphan Medicinal Product Designation for Modifier Gene Therapy Candidate Ocu410St for Treatment of Abca4-Associated Retinopathies Including Stargardt Disease
Ocugen Announces Compelling Preliminary Data for Ocu410—a Single Dose Novel Modifier Gene Therapy to Treat Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
No comment yet